Press Release4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral ...

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus, to enable ...

The company's proprietary Synthetic Super-Enhancers (SSEs) are engineered DNA elements that act as docking stations for transcription factors uniquely expressed in aggressive cancer cells. This ...

The traditional approach has two major shortcomings– low integration efficiency and heterogeneity in gene expression due to ...

A new AI model leverages deep learning to understand the binding of transcription factors to DNA, focusing on the process of ...

An international team of researchers has achieved an unprecedented milestone: the creation of mouse stem cells capable of ...

Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ...

Cell-free DNA can be used for non-invasive cancer detection and disease monitoring to enhance personalized medicine.

Researchers discovered that gene deserts, non-coding DNA regions, regulate heart and embryo development through enhancer ...

In 1937, President Franklin Roosevelt signed the National Cancer Act, launching a nationwide effort to combat the disease.

A trio of research papers from Stanford Medicine researchers and their international collaborators transforms scientists' understanding of how small DNA circles -; until recently dismissed as ...

Transcription activation of genes by estrogens is driven by enhancers, which are often located within the same Topologically Associating Domain (TAD) as non-targeted promoters. We investigated how ...